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Abstract 
Equipoise is advocated as a means of achieving high scientific and ethical standards in 
randomised trials. It is the belief that in each trial no arm is known to offer greater 
harm or benefit than any other arm. Clinicians who lack personal equipoise are 
advised to accept clinical or communal equipoise, based on current unresolved 
disagreement among the medical profession. Equipoise is mainly discussed in the 
literature as an issue for senior doctors and research directors. Limitations of 
professional equipoise are reviewed, and data on the neglected topic of patients' 
equipoise are reported using the example of breast cancer trials. In theory, a patient 
who gives informed and voluntary consent to enter a randomised trial has achieved 
the equilibrium of equipoise. In practice, equipoise among patients ranges from 
personal to proxy acceptance. 
 
 Equipoise as a means of managing uncertainty: personal, communal and proxy 
 
Introduction 
Equipoise is advocated as a means of achieving high scientific and ethical standards in 
randomised trials. It is the belief that, in each trial, no arm is known to offer greater 
harm or benefit than any other arm. This belief enables clinicians sincerely to 
recommend to their patients that they enter randomised trials(1). Clinicians who lack 
personal equipoise are advised to accept a communal position, collective or clinical 
equipoise based on current unresolved disagreement or uncertainty among the 
medical profession (2). Collective uncertainty about optimal choices, or communal 
equipoise, is cited as an ethical imperative to treat patients in trials, in order to 
maximise benefits to future patients (3). Despite claims that patients in trials tend to 
have better outcomes, so far there is little clear evidence for this (4).   
  Equipoise is mainly discussed as an issue for senior doctors, who may have to 
circumvent the effects on trials of bias among nurses and junior doctors. Silverman, for 
example, describes how junior doctors and nurses in his neonatal unit would select the 
coloured ball linked to their preferred treatment for each baby, instead of picking one 
at random. When he wrote the treatment arms on slips of paper and put each one in an 
envelope, the staff would hold up the envelopes to the light, in order to select the 
treatment by choice instead of by chance. Silverman described how he then made the 
envelopes opaque (5). He did not appear to consider the ethical dilemmas for nursing 
and junior medical staff who do not have equipoise, and yet are expected to enrol 
babies in trials, inform and consult with parents, and act as the main link between 
research, treatment and care of the family.  
  The concept of communal equipoise has been critically analysed, to support the 
conclusion that it cannot `do what it was hoped it could' (6). The author asks, what 
exactly is the `medical community'? How many of its members have to be uncertain, 
and how uncertain do they have to be, before communal equipoise can reasonably be 
claimed? Since complete unanimity is seldom achieved, can communal equipoise 
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almost always be claimed? How long can uncertainty reasonably be claimed to justify 
the later stages of a long trial? Does the uncertainty of a few specialists count for more 
than the `not-irrational hunch' shared by many doctors concerning certain treatments? 
Doctors are guided by experience, observation, tradition and other potentially 
valuable sources of knowledge besides randomised research; the nature and sources of 
communal medical knowledge, and therefore the grounds of medical ignorance, have 
not been clearly agreed. Advocates of trials claim that 85% of medical interventions are 
so far unevaluated, though evidence for this claim is uncertain (7). They also assert that 
the controlled experiment of a trial is more ethical than the `uncontrolled experiment' 
of routine but unevaluated interventions. Yet this claim plays on a double meaning of 
`uncontrolled'. Treatment which has not been subject to a controlled trial is 
`uncontrolled' in a strictly scientific sense, but is not necessarily `uncontrolled' in the 
everyday meaning of chaotic, irresponsible, casual and even callous, which the word 
can imply. 
  The literature on equipoise seldom mentions the patients' views. In theory, a patient 
who consents to enter a randomised trial has achieved equilibrium, and accepts the 
known risks and benefits of undertaking or of forgoing each treatment arm. Equipoise, 
in the literature, is usually implicitly confined to ignorance about the relative efficacy 
of the outcome of each treatment arm. Yet the patient's understanding of equipoise has 
to go beyond outcome to include process. For example, a women agreeing to enter the 
trial of adjuvant treatment for ductal carcinoma in situ (DCIS) would need to go 
beyond the scientific and philosophical abstract meaning of equipoise. She would have 
to consider the process, the likely experience of going through each of the treatment 
arms, their effects on her life and body and on people who depend on her, and the 
possible short and long term effects. In many trials, similar treatments are compared 
for relatively low risk disease. In some breast cancer trials, patients are randomised to 
very dissimilar treatment arms, at a time when they are shocked by the diagnosis, and 
fearful of an unexpectedly early death and of mutilation and distressing treatments. 
Many women are amazed when they are informed about the extent of medical 
uncertainty and the concepts of randomised trials and equipoise. For them to 
understand, evaluate and come to terms with the information and to arrive at, or to 
achieve, an intellectual and emotional state of equipoise can be a long hard struggle.   
  In theory, each woman would have to reach some kind of equilibrium about each of 
the options, although in some versions of the DCIS trial the arms range after surgery 
from annual observations only, to having tamoxifen, radiotherapy and chemotherapy. 
Can patients achieve equipoise? Do they wish go through the intellectual and 
emotional process of accepting the uncertainties and risks that equipoise and 
randomisation can entail? This paper reports part of a study of professional and public 
views on equipoise in breast cancer trials (8). 
 
Professional and public views on equipoise 
  In a multi-centre pilot study in England, during 1993 we interviewed 50 consecutive 
patients aged 33 to 83 after treatment for primary breast cancer (referred to as the 
treated women), and 40 doctors, nurses and radiographers aged 29 to 58, working in 
breast cancer in specialist centres or in general surgery units; 93 women, aged 50 to 73, 
replied to our questionnaire survey sent to 161 consecutive names on breast screening 
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lists (referred to as the screened women). A few of the treated women said that they 
had taken part in clinical breast cancer research, some said they thought they might 
have been involved, but they were unsure; with others, we thought from their replies 
and knowledge of the centre where they were treated that they might have been in 
trials but we were uncertain.  
  Our research raised ethical problems. We were asked by research ethics committees 
not to approach women until three months after their diagnosis of primary breast 
cancer, so we were relying on their memories of complex and distressing experiences. 
As breast cancer is a chronic disease, some women were still having treatment and 
others would eventually need further treatment, we had to be very careful to try not to 
affect their confidence in the professionals treating them. If an interviewee gave over-
optimistic responses about rates of mortality or the success of treatments we did not 
inform them about the actual rates, although we sent a short report to every 
respondent when the pilot stage was completed, with details about how they could 
obtain further information if they wished to. To respect confidentiality and privacy we 
did not see the patients' notes or discuss individuals with the staff caring for them, 
which is why the numbers enroled in research were uncertain. To check patients' notes 
for records on involvement in research is a complicated exercise; a study of 334 
women treated for invasive breast cancer in south-east England found that only 17 
case notes recorded that the woman took part in a clinical trial, 0.05 per cent (9). 
  Few of the health professionals had heard of the word `equipoise', though most 
accepted the concept. Table 1 shows that only a quarter of the professionals said they 
thought that individual doctors could achieve equipoise; still fewer said that the whole 
breast care team working on a trial could share equipoise, or that some patients could 
achieve it. One sister compared receiving a diagnosis of breast cancer to being on a 
ship with a tilting deck and everything is sliding into the sea (10). To learn about 
randomisation and the uncertainty concerning optimal treatment can seem like 
removing the last hope. `Complex' replies included discussion of the degrees of 
intellectual conviction and emotional commitment required, the types of people or of 
research interventions concerned, and `proxy equipoise' when staff and patients have 
faith in the consultant's convictions. They are content to rely on that and do not feel 
able or willing to form their own assessment. The high number of responses that could 
not simply be coded as `yes/no' illustrated how complex and ambiguous many 
respondents found the whole topic of breast cancer. 
  Equipoise is premised on uncertainty and ignorance, and respondents were asked for 
their views on informing patients about clinical uncertainty. Among the health 
professionals, 15% thought that women generally accepted current uncertainty about 
the nature and treatment of breast cancer when they were informed; 25% thought that 
women preferred to be informed; 15% thought that women were too distressed and 
preferred not to know; the rest gave other replies including discussion about how 
much the women and the range of relevant information varied. Responses varied 
widely from the view that patients were more trusting and confident when fully 
informed about uncertainty, to examples of women who were horrified by this 
information. When asked for their own views on current uncertainty about the nature, 
prevention and treatment of breast cancer, 32% of health professionals said they were 
`quite concerned' and the rest were equally divided between being `not worried', `very 
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concerned' or giving qualified replies. 
  Among the screened women, 14% ticked `most treatments have been tested' and 56% 
indicated their belief that current knowledge is too limited. Treated women were 
asked if they would want to be informed about current uncertainty if they were asked 
to take part in a trial; 68% said `yes', 4% said `no', and the others gave qualified replies. 
   
  All respondents were asked how they might react if they were in a position to be 
asked to join three kinds of breast cancer trials involving surgery, chemotherapy, and 
the preventative tamoxifen trial for women at above average risk of developing breast 
cancer. Although 53% of the professionals said they would agree to join the tamoxifen 
trial, in all the other replies from all three groups the refusals far exceeded agreement. 
Some professionals who supported randomisation in principle said they did not have 
equipoise for the actual trials discussed, or that they personally preferred the limited 
certainty of partially informed choice to the total uncertainty and powerlessness of 
being randomised. A radiotherapist and a senior nurse, who strongly supported 
randomised research in their general replies, changed when asked about their personal 
preference. The radiotherapist said that as someone used to making decisions she 
would not accept being randomised. The nurse said that she would choose to have all 
available treatments. Some treated women said they could not go through 
chemotherapy unless they were convinced that it was worthwhile; others said they 
wanted to have all available treatments, formally evaluated or not. Ethical ways of 
including people who do not have equipoise in randomised trials have been proposed 
(11). 
  Health professionals, screened and treated women were all asked for their views on 
their preferred methods of making or sharing decisions. The replies are summarised 
here into three categories, noted in other research (12 13): the patient actively deciding, 
with or without the doctor's advice; patients and doctors sharing decisions; the 
`passive' category when doctors decide for patients (see table 2). In relation to 
equipoise, `active deciders' tended to have a clearly preferred treatment although it is 
possible for understanding of uncertainty and acceptance of equipoise to support 
informed consent to be randomised. The sharers include those who are willing to 
consent to research, and the `passive' group include those who trust a clinician's 
decision to involve them in research. Table 2 reports subjective responses to our 
research questions and can only offer a rough indication of actual preferences and 
decision making. The responses may be affected by respondents' modesty or caution 
or uncertainty.   
  Whilst most screened women replied that they preferred `sharing', treated women 
were more likely to say that they wanted either an active or a passive role. They 
tended to report experiencing less consultation than they wanted. Almost half the 
treated women said they wanted an active part in research decisions, professionals 
were more likely to believe that women wanted a collaborative, and not an active, role. 
Discussions about `sharing' ranged from wishing to take a minor to a major part in 
decision-making. Discussions about the complications of actual experiences, and 
people's reasoning and qualifications to their replies contribute the most important 
data, and are given in the full research report (14).  
  Acceptance of equipoise could be affected by personal belief in the importance of 
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clinical research. When asked for their general views on breast cancer research, the 
treated women expressed rather more confidence than the professionals did in the 
benefits of research (reduces mortality and morbidity, increases knowledge, offers 
hope). The professionals were more concerned about problems of research (of `using' 
people, reducing choice, increasing anxiety) than the treated women were. However, 
professionals were more likely (83%) than the treated women (80%) and the screened 
women (22%) to say that trials are valuable in showing which treatments are harmful 
or useless.  
  Equipoise could also be affected by personal motives for or against supporting 
research, and a selection of replies on motives is given here. Some of the questions 
were slightly different for the three groups of respondents. One main motive for 
taking part in research, `to help other people', was given by 92% of treated women and 
82% of professionals; 50% of screened women gave `to help to save other people's life' 
as a motive, and 63% `to improve treatments in the future'. The other main motive was 
`to help to find the answers', supported by 80% of treated women and 92% of 
professionals; 54% of screened women agreed with the motive `to help to increase 
medical knowledge'. A third motive `to increase my own chances of getting good care' 
was supported by 67% of professionals, 43% of treated women and 40% of screened 
women.  
  The following motives were given for refusing to take part in research: `could not 
accept being randomised' 58% of treated women, 56% of screened women, 39% of 
professionals; `if I objected to the trial design' 85% of treated women, 97% of 
professionals; `dislike lack of choice' 71% of treated women; `would want to share in 
choosing my treatment' 56% of screened women. Treated women emphasised their 
desire for personal choice in contrast to impersonal chance. `I've done research myself, 
I know how important it is, but at that moment when I knew I had breast cancer I 
needed him [consultant] to know what was the best decision for me'.   
 
Conclusion 
  The pilot study raises questions which we intended to follow up in a larger project. 
We are cautious about generalising from the initial findings. However, the responses 
from a range of centres and from the 90 lengthy interviews suggest widespread 
ignorance and unease about equipoise, which cast doubt on the status of equipoise as 
the linchpin of ethical breast cancer trials. Equipoise may be more widely accepted in 
research about other diseases, with lower mortality and morbidity rates, less disparity 
between treatment arms, and shorter treatment episodes. The collective uncertainty 
which can justify equipoise did not seem to be shared by many of our respondents, 
only 23% of health professionals said that they were `very concerned' about the limits 
of current medical knowledge. This reported level of concern does not fit with the 
rising mortality rates for breast cancer in the UK and the seriously inadequate 
knowledge about the origins, prevention and treatment of the disease(15), reported in 
the professional (16) and the popular press (17). Until health professionals and the 
public are more aware and concerned about current uncertainty and ignorance, 
relatively few people will have personal equipoise. Communal equipoise will rest on 
the views of a minority of experts rather than on a majority view, and a consensus of 
equipoise among members of the research teams will be harder to achieve. 
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  Nurses discuss trials with many women who are considering whether to enter them; 
nurses, radiographers and other staff support women during the trials. The degree of 
equipoise shared by the breast cancer team, their commitment, even their unspoken 
reservations, can affect women's decisions to enter and to continue in trials.  
  Our research work included writing and evaluating a booklet for women who are 
asked to take part in breast cancer trials. The booklet explains research terms and 
concepts, such as clinical uncertainty and equipoise, which underlie informed consent 
to research. It suggests questions for women to use if they wish to discuss research 
with the breast care team, to help professionals and patients to share clear information. 
This exchange of views can increase mutual understanding, and could help towards 
planning more widely acceptable trials, which meet high professional and public 
standards of equipoise. Attempts to interest the cancer information agencies in 
publicising the booklet, or a similar version, have failed. There appears to be much 
reluctance to inform the public about the uncertainty that underlies equipoise, and the 
mass media tends to report the successes and hopes of cancer researchers rather than 
the extent of current ignorance and uncertainty.  
  Replies, in the breast cancer study, to the questions on uncertainty and sharing 
decisions, suggest that patients fall into three groups: those who wish to share in 
making decisions with their doctors, those who prefer their doctors to decide for them, 
and those who wish to be the `main decider' about proposed treatment. In the breast 
cancer study, women were concerned to be involved in decisions about research than 
about treatment, although clinical research usually overlaps with treatment. In order 
to become informed and involved, patients have to be honestly told about uncertainty 
and risk. Some clinicians find this information too complex and distressing to share 
with their patients, some argue that respect for informed consent can put too much 
constraint on clinical trials (18). Our interviews revealed that some health professionals 
give over-optimistic estimations of success rates of treatment, and under-estimate the 
urgent need for research. 
  A partial solution to the conflict between informing patients honestly yet protecting 
them from extreme anxiety can be for clinicians to work out with their patients how 
much they wish to be informed and involved in decision-making. It is important not to 
confuse poor communication and information-giving, and lack of support and time, 
with patients' seeming lack of interest or understanding. Efforts to share informed 
decision making may demand more time than staff are able to give. There are resource 
implications which include time to inform practitioners and to help them to accept the 
limitations of current knowledge as well to help their patients to come to terms with 
these uncertainties. The degree to which patients wish to be involved in decisions 
about trials will be influenced by their position on the equipoise spectrum: whether 
they want to think through all the options and come to a committed personal decision, 
or they accept communal equipoise as a kind of majority view, or they wish to defer to 
their doctor's decision and accept professional equipoise by proxy. 
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Table 1.  Views of 40 breast cancer professionals on whether equipoise is possible for 
individual doctors, for the whole breast care team, or for certain patients. 
 
% repliesdoctorsbreast care patients 
team 
 
yes251318 
no355838 
complex201018 
don't know13 810 
no reply 81318 
 
Note: Responses have been recorded as percentages to allow easier comparison; they 
are rounded up to the nearest number so that some columns show over 100% 
response. 
 
 
Table 2.  Summary of views of all three groups on making and sharing decisions about  
  treatment and research 
 
% replies 
    active sharing passive  other 
         response 
 
screened women on  
  preferred treatment  
  decision method11 73  710 
treated women on    
  preferred treatment  
  decision method16 34 2030 
treated women on    
  treatment decision    
  method experienced     30*2644 
treated women on  
  preferred research  
  decision method47 21 24 9 
professionals on 
  preferred research 
  decision method29 38 1221 
 
*  In these interviews, women described how they discussed options with their doctor. 
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